Biopharmaceuticals

Human brain
#AIS #Basking Biosciences #Biopharmaceuticals #Biosciences #Microfluidics #Stroke therapy

Basking Biosciences reports promising stroke therapy results

Basking Biosciences, a clinical-stage biopharmaceutical company developing a first-in-class, targeted, reversible thrombolytic therapy for acute ischemic stroke (AIS), has announced the publication of preclinical research in Communications Biology, a Nature Portfolio journal. The study shows that its lead candidate, BB-031, restores blood flow in a microfluidic model of arterial occlusion… Read More

#News

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top biopharma companies report 4% market growth in Q3 2025

The top 20 global biopharmaceutical companies experienced mixed individual market capitalisation performances in Q3 2025, with those experiencing robust pipeline progress reaping success.   This resulted in a 4% quarter-on-quarter (QoQ) increase in their combined market capitalisation from $3.7 trillion on 30 June 2025 to $3.8 trillion on 30 September 2025,… Read More

#Business & Investment #News #Trends & Analysis

#Automation #Biopharmaceuticals #Drug discovery #Sustainability

Key themes from ELRIG Drug Discovery 2025

This year’s ELRIG Drug Discovery event, which took place at the ACC in Liverpool, was intended as a celebration of the sector, uniting scientists, academics and industry professionals towards the common goal of improving human health. As such the theme for Drug Discovery 2025 was “A Festival of Life Science”… Read More

#News

#Biopharmaceuticals #Drug discovery #High throughput screening #Sartorius

Advancing global health through innovation

This paid-for advertorial from Sartorius appeared in DDW Volume 26 – Issue 4, Fall 2025 The global health landscape is complex and constantly shifting, presenting multifaceted challenges for the pharmaceutical industry. To keep pace, companies must deliver more targeted therapies in less time, often with fewer resources. Advances in areas… Read More

#Exclusive Content

#Association of the British Pharmaceutical Industry #Biopharmaceuticals #Pharmaceutical industry #UK government

UK pharma pricing discussions end in stalemate

The Association of the British Pharmaceutical Industry (ABPI) and the UK government have been unable to reach an agreement on changes to a controversial medicines payment scheme.  In April 2025, the ABPI and government agreed to bring forward a planned mid-scheme review of the 2024 Voluntary Scheme… Read More

#News #Trending News

Drug prices concept
#Biopharmaceuticals #Drug pricing #Pharmaceutical industry #United States

What international reference pricing could mean for US drug costs

Andrew Mignatti, Co-Founder and CEO of careviso, looks at the possibility of the United States (US) adopting international reference pricing and asks if it is possible to lower drug costs without undermining innovation.  Discussion around international reference pricing (IRP) is intensifying as policymakers search for ways to address persistently high… Read More

#Business & Investment #Exclusive Content #Opinion

Antibodies
#Absci #Antibodies #Biologics #Biopharmaceuticals #Clinical trials

Absci becomes clinical-stage company with clinical trial initiation

Biopharmaceutical company Absci has transitioned into a clinical-stage organisation with the dosing of patients in its Phase I clinical trial of ABS-101. ABS-101 is the company’s investigational anti-TL1A antibody targeting inflammatory bowel disease, engineered using Absci’s generative AI platform. “We are excited to advance ABS-101 into Phase I clinical trials,”… Read More

#News

#BIAL #Biopharmaceuticals #Neuroscience #Parkinson's #Rare diseases

BIAL to present at GBA1 Meeting 2025 on Parkinson’s treatment

BIAL, a biopharmaceutical company focused on neurosciences and rare diseases, will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held 5-7 June 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1… Read More

#News

Russell Abberley
#Appointment #Association of the British Pharmaceutical Industry #Biopharmaceuticals #UK

ABPI announces new president-elect

The Association of the British Pharmaceutical Industry (ABPI) has announced that Russel Abberley, the Vice President and General Manager of Amgen UK and Ireland, will become the organisation’s new president, after having held the role on an interim basis.   Abberley will take up the role on 13… Read More

#News

#Biopharmaceuticals #Generics #Politics #Small molecules #United States

Trump directive aims to cut costs of prescription drugs

US President Trump has signed an executive order designed to lower the cost of prescription drug prices, which includes a win for manufacturers of small molecule drugs.  The order comes one day after the Trump administration instituted a national security report into the pharmaceutical industry, which is likely to be… Read More

#Business & Investment #News #Trending News

Female scientists working in a lab
#ABPI #Biopharmaceuticals #Collaboration #Pharmaceutical industry

Industry-academic collaborations vital for UK pharma workforce

A surge in apprenticeships, placements, and global research collaborations is strengthening the UK’s pharmaceutical workforce.  This is a summary of the key findings from the latest Industry and Academic Links Survey from the Association of the British Pharmaceutical Industry (ABPI).  As National Apprenticeship Week (10-14 February) begins, new figures highlight… Read More

#Business & Investment #News

#Biopharmaceuticals #Clarivate #Market reporting #Small molecules

Eleven drugs tipped for blockbuster status by 2030

Eleven drugs are projected to achieve blockbuster status or revolutionise treatment paradigms within five years, according to Clarivate’s 2025 Drugs to Watch report.  The drugs address critical challenges in areas such as obesity, oncology, and gene therapy, and are forecast to achieve blockbuster sales by 2030 or dramatically improve patient… Read More

#Editor's Choice #News #Trends & Analysis

#Biopharmaceuticals #Business #Market reporting

Half of 2023’s new drugs underperformed in their first year

Half of the 2023 US pharmaceutical launch class underperformed their pre-launch first year forecast while 39% overperformed. However, this is an improvement from prior years, with 54% underperforming and 35% overperforming when evaluating new product launches in the US from 2020-2023. These are the findings of a whitepaper by life… Read More

#Business & Investment #Editor's Choice #News

Endotoxin test
#ADME / Tox #Biopharmaceuticals #Drug toxicity #Endotoxins #Technical Note

Technical Note: Targeted and efficient endotoxin removal

A new Technical Note is now available to download, brought to you by Astrea Bioseparations, ‘EtoxiClear, a Chromatography Adsorbent for Effective Removal of Endotoxins from Biopharmaceuticals‘. In this Technical Note you will learn more about: Targeted and efficient endotoxin removal: EtoxiClear is a highly effective chromatography affinity adsorbent, specifically… Read More

#News